All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly USA, LLC, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How can clinicians reduce treatment burden while supporting QoL and long-term survivorship for patients with cHL?

By Amy Hopkins

Share:

Featured:

Justin FerdinandusJustin Ferdinandus

Nov 18, 2026

Learning objective: After reading this article, learners will be able to discuss how clinicians may support quality of life and long-term survivorship while reducing treatment burden in patients with classical Hodgkin lymphoma.


Do you know... In the HD21 trial, what impact did the BrECADD regimen have on gonadal function recovery vs eBEACOPP in patients with cHL?

The Lymphoma Hub was pleased to speak with Justin Ferdinandus, University Hospital Cologne, Cologne, DE. We asked, How can clinicians reduce treatment burden while supporting QoL and long-term survivorship for patients with cHL? 

How can clinicians reduce treatment burden and support QoL/survivorship in patients with cHL?

In this interview, Ferdinandus discusses key long-term considerations around therapeutic goals, treatment burden, and quality of life (QoL) in patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving first-line treatment.  

Key points 

  • With cure rates exceeding 90%, minimizing the long-term impact of treatment is increasingly important in first-line cHL; treatment burden should be reduced wherever possible without compromising the efficacy achieved with current therapies.1,2 
  • First-line treatment selection should account for patient age, disease stage, prognostic factors, and bulky disease, which may influence treatment intensity and long-term outcomes.1,3 
    • Young patients with cHL may experience late treatment effects, including comorbidities, organ dysfunction, fertility issues, and neuropathy.1,3 
  • Young patients, particularly those who have not completed family planning, should be counseled on fertility preservation before the first cycle of treatment.1–3  
  • Results from the phase III HD21 trial (NCT02661503) of brentuximab vedotin + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone (BrECADD) vs escalated doses of bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone (eBEACOPP) in patients with advanced-stage cHL, showed higher gonadal function recovery rates with BrECADD, potentially linked to the omission of procarbazine.4,5 
    • Overall, 85.6% of male and 95.3% of female patients who received BrECADD recovered gonadal function within 4 years after treatment vs 39.2% and 72.5% of patients, respectively, with eBEACOPP.4,5  
    • After therapy, the 5-year incidence of parenthood was significantly higher in males who received BrECADD vs eBEACOPP (9.3% vs 3.3%; p = 0.014).5 
  • Strategies to minimize long-term toxicity include reducing the risk of persistent neuropathy, particularly in younger patients; avoiding bleomycin-associated pulmonary toxicity where appropriate; and working with radio-oncologists to minimize radiotherapy exposure and field size.1–3 
  • As programmed cell death protein 1 (PD-1) inhibitors enter the first-line setting for advanced-stage cHL, clinicians should consider the potential for immune-related toxicities, including hypophysitis, pancreatitis, and nephritis, as well as other rare, potentially serious high-grade toxicities.1,6,7 
  • Treatment burden extends beyond adverse events captured in conventional toxicity assessments to include treatment duration and number of infusion visits.8,9 
    • In the HD18 trial (NCT00515554), positron emission tomography (PET)-guided treatment reduction from eight to four cycles of eBEACOPP led to a significantly shorter time to recovery from fatigue (hazard ratio [HR], 1.41; p = 0.008) and descriptively shorter time to return to work (HR, 1.24; p = 0.084) in PET-2-negative patients.10 
  • Survivorship planning for patients with advanced-stage cHL should include clear guidance on whom to consult about late effects, fertility issues, secondary malignancies, and the detection of relapse.1,11 
  • Treatment of advanced-stage cHL should balance efficacy with minimizing long-term treatment burden through individualized treatment selection, proactive fertility counseling, and strategies to reduce toxicity, with comprehensive survivorship planning embedded into care.1,3 

This educational resource is independently supported by Takeda. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.  

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

In which lymphoma subtypes do you currently use next-generation sequencing as part of the diagnostic work-up in your practice?